Systemic Lupus Erythematosus Treatment Companies

FDA Approves Phase 1 Trial for CNTY-101: The FDA has cleared the path for a Phase 1 trial of CNTY-101, a novel drug targeting a specific protein involved in lupus inflammation. This is a promising development for patients who haven't responded to conventional therapies.

Lupus Therapeutics and AbbVie Partner: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, has joined forces with AbbVie to support clinical trial recruitment for upadacitinib, a drug already approved for other inflammatory conditions. This collaboration aims to accelerate research and access for SLE patients.

• Sanofi (France)


• Hoffmann-La Roche Ltd (Switzerland)


• Novartis AG (Switzerland)


• Pfizer Inc. (US)


• GlaxoSmithKline plc (UK)


• AstraZeneca (UK)


• Eli Lilly and Company (US)


• Bristol-Myers Squibb Company (US)


• Amgen Inc. (US)


• Anthera (US)


• Johnson & Johnson Services, Inc. (US)